|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race |
| Stephen Freedland, MD |
| Stephen Freedland joins Alicia Morgans to discuss a retrospective analysis of the Medicare database from January 2009-Dec 2018 on the real-world use of advanced therapies over time and the use of patterns among racial minorities that are often under-represented in clinical trials. |
|
|
|
|
|
|
|
|
|
|
|
| Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study |
| Oliver Sartor, MD |
| Oliver Sartor joins Alicia Morgans to discuss a real-world clinical outcomes study of sequential novel antihormonal therapy (abiraterone or enzalutamide) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. |
|
|
|
|
|
|
|
|
|
|
|
| Real-World Treatment Patterns Among Patients Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in Community Oncology Settings |
| Daniel George, MD |
| Daniel George presents an assessment of the real-world utilization of effective combination therapies in the first-line treatment of mCSPC in oncology practice. To do so, the authors utilized the ConcertAI Oncology Dataset to examine electronic medical record (EMR) data from a network of U.S.-based oncology practices. |
|
|
|
|
|
| Real-World First-Line (1L) Treatment Patterns in Patients (Pts) with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in a U.S. Health Insurance Database |
| Umang Swami, MD |
| Umang Swami shares data from an assessment of the real-world utilization of effective combination therapies as first-line treatment in insured patients in the U.S. with mCSPC. The data demonstrated that real-world utilization of treatment approaches that have been shown to improve survival in men with mCSPC is generally poor, even as of 2019. While further work is needed to understand the reasons for the underutilization of proven life-prolonging therapy, increased efforts are needed to disseminate these therapies to patients. |
|
|
|
|
|
|
|
|
|
|
| Real-World Utilization of Advanced Therapies and Racial Disparity Among Patients with Metastatic Castration-Sensitive Prostate Cancer: A Medicare Database Analysis |
| Stephen Freedland, MD |
| Stephen Freedland presents results of an analysis of Medicare data regarding real-world utilization of these agents in men with mCSPC. Based on this large and nationally representative sample of men with mCSPC patients, treatment intensification was uncommonly used with some, but not dramatic, an improvement over time. Importantly, they further showed that treatment intensification was less commonly used in Black and Hispanic patients. |
|
|
|
|
|
| Evaluation of PSA Progression After Initiation of Enzalutamide or Abiraterone: Real-World Data on mCRPC |
| Fernando López-Campos, MD |
| Fernando López-Campos evaluates the significance of an early PSA increase in mCRPC patients treated with enzalutamide or abiraterone. PSA progression at 4 weeks after enzalutamide or abiraterone is significantly associated with shorter OS and may help identify patients not benefitting from enzalutamide or abiraterone before clinical or radiographic progression. PSA pattern progression and its association with OS might differ depending on the drug used. |
|
|
|
|
|
| Real-World Clinical Outcomes Study of Sequential Novel Antihormonal Therapy (NAH) or Ra-223 Treatment of mCRPC That Progressed After First-Line NAH |
| Oliver Sartor, MD |
| Oliver Sartor presents an assessment of real-life clinical outcomes in patients with mCRPC treated in the USA who received sequential first-line (1L)/second-line (2L) NAH (abiraterone/enzalutamide or enzalutamide/abiraterone) or switched to a different mechanism of action (alpha-emitter Ra-223) after progression on 1L NAH. |
|
|
|
|
|
| Genomic Landscape of Advanced Prostate Cancer In Racial Minority Populations: Real-World Experience In A Safety-Net Hospital Oncology Clinic |
| Tamer Khashab, MD |
| Tamer Khashab presents genomic data derived from a retrospective analysis of patients treated at a community-focused academic healthcare system in Texas that serves a higher percentage of Hispanic and African American patients with prostate cancer. |
|
|
|
|
|
| Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence |
| Lawrence Mbuagbaw, MD, MPH, Ph.D. |
| Lawrence Mbuagbaw presents results of a real-world study evaluating clinical outcomes of patients when Radium-223 was used early (second-line) or late (third or later lines) among men with mCRPC. Patients who received Radium-223 in second-line versus third-line or later had better outcomes. Additionally, patients who received Radium-223 early received less chemotherapy, but had better survival. |
|
|
|
|
|
|
